Drug
Jnj 26489112
Jnj 26489112: highest development phase Phase 2, developed by Johnson & Johnson. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| JNJ-26489112 NCT00579384 | Phase 2 | Photosensitive Epilepsy |
Latest
No recent events.
Follow Jnj 26489112 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.